Abstract
Introduction: CI-980 is a novel chemotherapeutic agent that inhibits polymerization of tubulin. Preclinical studies have indicated a high level activity of this agent against various tumor cell lines. Methods: 13 malignant melanoma patients who had failed prior chemotherapy and/or immunotherapy and 13 hormone refractory prostate cancer patients, including 4 who had received prior chemotherapy, were treated in 2 separate NCI-supported clinical trials. Subjects received a recommended phase II dose of CI-980 of 4.5 mg/m2/day by continuous infusion for 72 hours every 3 weeks. Results: No activity was seen in either study. Toxicity was tolerable with neutropenia being the most common, significant toxicity. Among the melanoma patients, 15% and 31% developed grade 3 and grade 4 neutropenia, while 7% and 38% of the prostate patients developed grade 3 and grade 4 neutropenia, respectively. Conclusions: CI-980 at this dose and schedule is ineffective against malignant melanoma and hormone refractory prostate cancer.
Original language | English (US) |
---|---|
Pages (from-to) | 187-191 |
Number of pages | 5 |
Journal | Investigational New Drugs |
Volume | 18 |
Issue number | 2 |
DOIs | |
State | Published - 2000 |
Externally published | Yes |
Keywords
- Chemotherapy
- Clinical trial
- Malignant melanoma
- Prostate cancer
ASJC Scopus subject areas
- Oncology
- Pharmacology
- Pharmacology (medical)